MXPA02011218A - Composiciones y metodos para el tratamiento de cancer. - Google Patents
Composiciones y metodos para el tratamiento de cancer.Info
- Publication number
- MXPA02011218A MXPA02011218A MXPA02011218A MXPA02011218A MXPA02011218A MX PA02011218 A MXPA02011218 A MX PA02011218A MX PA02011218 A MXPA02011218 A MX PA02011218A MX PA02011218 A MXPA02011218 A MX PA02011218A MX PA02011218 A MXPA02011218 A MX PA02011218A
- Authority
- MX
- Mexico
- Prior art keywords
- thalidomide
- cancer
- treatment
- methods
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Esta invencion se refiere a las composiciones que contienen talidomida y otro medicamento anti-cancer que puede utilizarse en el tratamiento o prevencion de cancer. Los medicamentos anti-cancer preferidos son inhibidores de la topoisomerasa. Una composicion particular contiene talidomida, o una sal, solvato o clatrato farmaceuticamente aceptable de este, e irinotecano. La invencion tambien se refiere a los metodos de tratamiento o prevencion de cancer que consisten en la administracion de un medicamento talidomida y otro medicamento anti-cancer a un paciente en necesidad de un tratamiento o prevencion como este. La invencion ademas se refiere a los metodos para reducir o evitar efectos colaterales adversos asociados con la administracion de quimioterapia o radioterapia, que consisten en la administracion de talidomida a un paciente en necesidad de tal reduccion o evitacion.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20414300P | 2000-05-15 | 2000-05-15 | |
PCT/US2001/015327 WO2001087307A2 (en) | 2000-05-15 | 2001-05-10 | Compositions and methods for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA02011218A true MXPA02011218A (es) | 2004-08-19 |
Family
ID=22756804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA02011218A MXPA02011218A (es) | 2000-05-15 | 2001-05-10 | Composiciones y metodos para el tratamiento de cancer. |
Country Status (19)
Country | Link |
---|---|
US (2) | US7435726B2 (es) |
EP (1) | EP1307197B1 (es) |
JP (1) | JP5409981B2 (es) |
KR (1) | KR100790589B1 (es) |
AR (1) | AR029084A1 (es) |
AT (1) | ATE322266T1 (es) |
AU (2) | AU6147401A (es) |
BR (1) | BR0110877A (es) |
CA (1) | CA2408707C (es) |
DE (1) | DE60118571T2 (es) |
DK (1) | DK1307197T3 (es) |
ES (1) | ES2258084T3 (es) |
HK (1) | HK1054502A1 (es) |
MX (1) | MXPA02011218A (es) |
NZ (1) | NZ522767A (es) |
PT (1) | PT1307197E (es) |
TW (1) | TWI289449B (es) |
WO (1) | WO2001087307A2 (es) |
ZA (1) | ZA200209638B (es) |
Families Citing this family (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050192360A1 (en) * | 1999-04-14 | 2005-09-01 | Li Chiang J. | Method of treatment of pancreatic cancer |
ES2290091T3 (es) * | 2000-11-30 | 2008-02-16 | The Children's Medical Center Corporation | Sintesis de enantiomeros de 4-amino-talidomida. |
US20020128228A1 (en) * | 2000-12-01 | 2002-09-12 | Wen-Jen Hwu | Compositions and methods for the treatment of cancer |
US6440738B1 (en) * | 2001-02-08 | 2002-08-27 | Isis Pharmaceuticals, Inc. | Antisense modulation of casein kinase 2-beta expression |
WO2002078679A2 (en) * | 2001-03-29 | 2002-10-10 | Topo Target Aps | Succinimide and maleimide derivatives and their use as topoisomerase ii catalytic inhibitors |
AU2002334595B2 (en) * | 2001-09-24 | 2007-03-01 | Tosk, Inc. | Reduced toxicity cisplatin formulations and methods for using the same |
US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
CA2383259A1 (en) * | 2002-04-23 | 2003-10-23 | Celator Technologies Inc. | Synergistic compositions |
US20080075762A1 (en) * | 2001-10-03 | 2008-03-27 | Paul Tardi | Compositions for delivery of drug combinations |
US20080249183A1 (en) * | 2001-11-29 | 2008-10-09 | Steiner Mitchell S | Treatment of androgen-deprivation induced osteoporosis |
US20070197664A1 (en) * | 2001-11-29 | 2007-08-23 | Steiner Mitchell S | Prevention and treatment of androgen-deprivation induced osteoporosis |
EP1769795B1 (en) * | 2001-12-03 | 2013-07-24 | Bayer HealthCare LLC | Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers |
AU2002366310A1 (en) * | 2001-12-14 | 2003-06-30 | Kyowa Engineering Co., Ltd. | Method of inducing apoptosis and compositions therefor |
JPWO2003080077A1 (ja) * | 2002-03-26 | 2005-07-21 | 萬有製薬株式会社 | 抗腫瘍性インドロピロロカルバゾール誘導体と他の抗がん剤との併用 |
US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
CN1705439A (zh) * | 2002-04-12 | 2005-12-07 | 细胞基因公司 | 干细胞和祖细胞分化的调节、鉴定及其应用 |
EP1496880A4 (en) * | 2002-04-24 | 2007-12-12 | Res Dev Foundation | SYNERGISTIC EFFECTS OF NUCLEAR TRANSCRIPTION FACTOR NF-kB INHIBITORS AND ANTINEOPLASTIC AGENTS |
JP2005530780A (ja) * | 2002-05-17 | 2005-10-13 | セルジーン・コーポレーション | 癌および他の疾患を治療および管理するための選択的サイトカイン阻害薬を用いた方法および組成物 |
US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
USRE48890E1 (en) | 2002-05-17 | 2022-01-11 | Celgene Corporation | Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation |
US7968569B2 (en) * | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US20100129363A1 (en) * | 2002-05-17 | 2010-05-27 | Zeldis Jerome B | Methods and compositions using pde4 inhibitors for the treatment and management of cancers |
US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
NZ584663A (en) * | 2002-05-17 | 2011-09-30 | Celgene Corp | Use of immunomodulatory amino-dione derivatives for treating leukemia |
EP1523318A4 (en) * | 2002-06-24 | 2007-07-04 | Res Dev Foundation | TREATMENT OF HUMAN MULTIPLE MYELOMA BY CURCUMIN |
US20040034099A1 (en) * | 2002-06-27 | 2004-02-19 | Ramsey Beverly J. | Pharmaceutical composition |
JP2006510606A (ja) * | 2002-10-15 | 2006-03-30 | セルジーン・コーポレーション | 骨髄異形成症候群を治療および管理するための選択的サイトカイン阻害剤の使用方法およびそれを含む組成物 |
US8404717B2 (en) * | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes using lenalidomide |
US8404716B2 (en) * | 2002-10-15 | 2013-03-26 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US11116782B2 (en) | 2002-10-15 | 2021-09-14 | Celgene Corporation | Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine |
US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
JP2006507324A (ja) * | 2002-11-06 | 2006-03-02 | セルジーン・コーポレーション | 骨髄増殖性疾患を治療および管理するための選択的サイトカイン阻害薬を含む組成物およびその使用法 |
BR0316057A (pt) * | 2002-11-06 | 2005-09-20 | Celgene Corp | Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit |
JP2006522088A (ja) * | 2003-03-31 | 2006-09-28 | ファイザー・インク | ポリ(adp−リボース)ポリメラーゼの三環系阻害剤の塩 |
CL2004001004A1 (es) * | 2003-05-19 | 2005-03-18 | Upjohn Co | Combinacion farmaceutica que comprende irinotecan y revimid para tratar el mieloma multiple. |
WO2004113502A2 (en) * | 2003-06-20 | 2004-12-29 | Avalon Pharmaceuticals, Inc. | Identification of therapeutic agents using genetic fingerprinting |
US7264819B2 (en) * | 2003-06-23 | 2007-09-04 | Anticancer, Inc. | Lyase treatment for P. carinii |
WO2005020908A2 (en) * | 2003-08-26 | 2005-03-10 | Research Development Foundation | Selective inhibitors of stat-3 activation and uses thereof |
CA2536380A1 (en) | 2003-08-26 | 2005-02-26 | Research Development Foundation | Osteoclastogenesis inhibitors and uses thereof |
UA83504C2 (en) | 2003-09-04 | 2008-07-25 | Селджин Корпорейшн | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US20050100529A1 (en) * | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
AU2004288714A1 (en) * | 2003-11-06 | 2005-05-26 | Celgene Corporation | Methods and compositions using thalidomide for the treatment and management of cancers and other diseases. |
CN101966183A (zh) * | 2003-12-02 | 2011-02-09 | 细胞基因公司 | 用于治疗和控制血红蛋白病和贫血病的方法和组合物 |
EP1694660B1 (en) * | 2003-12-12 | 2009-04-08 | Quiral Quimica Do Brasil | Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions |
EP1722777A2 (en) * | 2004-02-20 | 2006-11-22 | Arqule, Inc. | Use of beta-lapachone for the treatment of pancreatic cancer |
CA2556823A1 (en) * | 2004-02-20 | 2005-09-09 | Arqule, Inc. | Use of beta-lapachone for the treatment of lung cancer |
EP2033639A2 (en) * | 2004-02-20 | 2009-03-11 | Arqule, Inc. | Beta-lapachone for the treatment of colon cancer |
US7781393B2 (en) | 2004-02-25 | 2010-08-24 | Dana-Farber Cancer Institute, Inc. | Methods for inhibiting tumor cell growth |
US20100028339A1 (en) | 2004-03-29 | 2010-02-04 | Cheng Jin Q | Compositions including triciribine and trastuzumab and methods of use thereof |
US20110008327A1 (en) | 2004-03-29 | 2011-01-13 | Cheng Jin Q | Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof |
US20100009929A1 (en) | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof |
LT2574341T (lt) | 2004-03-29 | 2017-09-11 | University Of South Florida | Navikų ir vėžio efektyvus gydymas triciribino fosfatu |
US20100009928A1 (en) * | 2004-03-29 | 2010-01-14 | Cheng Jin Q | Compositions including triciribine and taxanes and methods of use thereof |
US20100173864A1 (en) | 2004-03-29 | 2010-07-08 | Cheng Jin Q | Compositions including triciribine and one or more platinum compounds and methods of use thereof |
MXPA06011798A (es) * | 2004-04-14 | 2007-01-16 | Celgene Corp | Metodos de uso y composiciones que comprenden compuestos inmunomoduladores para el tratamiento y manejo de sindromes mielodisplasticos. |
CA2563207A1 (en) * | 2004-04-14 | 2005-11-24 | Celgene Corporation | Use of selective cytokine inhibitory drugs in myelodysplastic syndromes |
CA2562904C (en) * | 2004-04-27 | 2013-07-02 | Wellstat Biologics Corporation | Cancer treatment using viruses and camptothecins |
US20090010886A1 (en) * | 2004-05-05 | 2009-01-08 | Celgene Corporation | Method for the Treatment of Myeloproliferative Diseases Using(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2- Methylsulfonylethyl]-4- Acetylaminoisoindoline-1,3- Dione |
CN1984651A (zh) * | 2004-05-05 | 2007-06-20 | 细胞基因公司 | 使用选择性细胞因子抑制药治疗和控制癌症和其它疾病的方法和组合物 |
US20060270707A1 (en) * | 2005-05-24 | 2006-11-30 | Zeldis Jerome B | Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus |
AU2006257664B2 (en) * | 2005-06-14 | 2013-01-10 | Protox Therapeutics Incorporated | Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins |
US20070066512A1 (en) * | 2005-09-12 | 2007-03-22 | Dominique Verhelle | Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels |
US20080138295A1 (en) * | 2005-09-12 | 2008-06-12 | Celgene Coporation | Bechet's disease using cyclopropyl-N-carboxamide |
CN1870631B (zh) * | 2005-11-11 | 2010-04-14 | 华为技术有限公司 | 媒体网关的门控方法 |
US20070155791A1 (en) * | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
WO2007089043A1 (ja) * | 2006-02-03 | 2007-08-09 | Takeda Pharmaceutical Company Limited | リポソーム製剤 |
JP2010500050A (ja) * | 2006-04-27 | 2010-01-07 | シェノイ,ナルマダ,アール. | 身体通路の疾病を治療又は予防する組成物及び方法 |
CL2007002218A1 (es) | 2006-08-03 | 2008-03-14 | Celgene Corp Soc Organizada Ba | Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa. |
US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
EP2014651A1 (en) * | 2007-07-12 | 2009-01-14 | Exonhit Therapeutics SA | Compounds and methods for modulating Rho GTPases |
WO2009020590A1 (en) * | 2007-08-07 | 2009-02-12 | Celgene Corporation | Methods for treating lymphomas in certain patient populations and screening patients for said therapy |
US20100311683A1 (en) * | 2007-11-01 | 2010-12-09 | Beach C L | Cytidine analogs for treatment of myelodysplastic syndromes |
US20090192098A1 (en) * | 2007-11-21 | 2009-07-30 | Oxigene, Inc. | Method for treating hematopoietic neoplasms |
US20090137631A1 (en) * | 2007-11-22 | 2009-05-28 | National Yang-Ming University | Methods and pharmaceutical compositions for regulation of g- and/or gc-rich nucleic acid expression |
US8741917B2 (en) | 2009-01-15 | 2014-06-03 | Rutgers, The State University Of New Jersey | Benzo [C] phenanthridines as antimicrobial agents |
WO2010127307A1 (en) | 2009-04-30 | 2010-11-04 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
US8933096B2 (en) | 2010-06-09 | 2015-01-13 | Rugers, The State University of New Jersey | Antimicrobial agents |
WO2011163610A2 (en) | 2010-06-25 | 2011-12-29 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
WO2012092485A1 (en) | 2010-12-31 | 2012-07-05 | Anthrogenesis Corporation | Enhancement of placental stem cell potency using modulatory rna molecules |
KR101369936B1 (ko) * | 2011-12-28 | 2014-03-06 | 연세대학교 산학협력단 | 탈리도마이드를 포함하는 루프스 신염 치료용 약학 조성물 |
WO2013106756A2 (en) | 2012-01-13 | 2013-07-18 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
US9475783B2 (en) | 2012-03-21 | 2016-10-25 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
WO2014180882A2 (en) * | 2013-05-07 | 2014-11-13 | Universitat De Barcelona | Treatment of brain metastasis from cancer |
US20170080093A1 (en) * | 2013-10-22 | 2017-03-23 | Tyme, Inc. | Tyrosine Derivatives And Compositions Comprising Them |
US9458150B2 (en) | 2013-11-08 | 2016-10-04 | Rutgers, The State University Of New Jersey | Antimicrobial agents |
MX2017002382A (es) | 2014-08-22 | 2017-05-17 | Celgene Corp | Metodos para tratar el mieloma multiple con compuestos imunomodulares en combinacion con anticuerpos. |
EP3313818B1 (en) | 2015-06-26 | 2023-11-08 | Celgene Corporation | Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers |
JP2018523712A (ja) | 2015-08-18 | 2018-08-23 | マテオン セラピューティクス, インク.Mateon Therapeutics, Inc. | 腫瘍に対する免疫調節療法を向上させる為のvdasの使用 |
WO2017147316A1 (en) | 2016-02-25 | 2017-08-31 | Taxis Pharmaceuticals, Inc. | Synthetic processes and intermediates |
KR101851470B1 (ko) | 2016-12-19 | 2018-06-11 | 한림대학교 산학협력단 | 퀘세틴이 함유된 유방암 예방 및 치료를 위한 약제학적 조성물 |
EP3600298A4 (en) | 2017-03-30 | 2020-11-11 | Taxis Pharmaceuticals, Inc. | SYNTHETIC PROCESSES AND SYNTHETIC INTERMEDIATE PRODUCTS |
US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6019790A (ja) | 1983-07-14 | 1985-01-31 | Yakult Honsha Co Ltd | 新規なカンプトテシン誘導体 |
US5422344A (en) * | 1990-05-08 | 1995-06-06 | The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Method of treating retroviral infections in mammals |
AU1531492A (en) | 1991-02-14 | 1992-09-15 | Rockefeller University, The | Method for controlling abnormal concentration tnf alpha in human tissues |
US5629327A (en) | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
US5643915A (en) | 1995-06-06 | 1997-07-01 | Andrulis Pharmaceuticals Corp. | Treatment of ischemia/reperfusion injury with thalidomide alone or in combination with other therapies |
US5654312A (en) | 1995-06-07 | 1997-08-05 | Andrulis Pharmaceuticals | Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents |
GB9523493D0 (en) * | 1995-11-16 | 1996-01-17 | British Biotech Pharm | Preparation of allyl succinate derivatives and starting materials therefore |
-
2001
- 2001-05-10 DE DE60118571T patent/DE60118571T2/de not_active Expired - Lifetime
- 2001-05-10 BR BR0110877-8A patent/BR0110877A/pt active Search and Examination
- 2001-05-10 CA CA2408707A patent/CA2408707C/en not_active Expired - Fee Related
- 2001-05-10 AU AU6147401A patent/AU6147401A/xx active Pending
- 2001-05-10 KR KR1020027015443A patent/KR100790589B1/ko not_active IP Right Cessation
- 2001-05-10 MX MXPA02011218A patent/MXPA02011218A/es active IP Right Grant
- 2001-05-10 AU AU2001261474A patent/AU2001261474B2/en not_active Ceased
- 2001-05-10 EP EP01935373A patent/EP1307197B1/en not_active Expired - Lifetime
- 2001-05-10 WO PCT/US2001/015327 patent/WO2001087307A2/en active IP Right Grant
- 2001-05-10 PT PT01935373T patent/PT1307197E/pt unknown
- 2001-05-10 JP JP2001583775A patent/JP5409981B2/ja not_active Expired - Fee Related
- 2001-05-10 NZ NZ522767A patent/NZ522767A/en not_active IP Right Cessation
- 2001-05-10 DK DK01935373T patent/DK1307197T3/da active
- 2001-05-10 ES ES01935373T patent/ES2258084T3/es not_active Expired - Lifetime
- 2001-05-10 AT AT01935373T patent/ATE322266T1/de active
- 2001-05-14 US US09/853,617 patent/US7435726B2/en not_active Expired - Fee Related
- 2001-05-15 AR ARP010102298A patent/AR029084A1/es unknown
- 2001-06-26 TW TW090111620A patent/TWI289449B/zh active
-
2002
- 2002-11-27 ZA ZA200209638A patent/ZA200209638B/en unknown
-
2003
- 2003-08-29 HK HK03106199A patent/HK1054502A1/xx not_active IP Right Cessation
-
2005
- 2005-03-09 US US11/074,849 patent/US20050148524A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE60118571T2 (de) | 2007-02-01 |
DE60118571D1 (de) | 2006-05-18 |
BR0110877A (pt) | 2003-03-11 |
EP1307197B1 (en) | 2006-04-05 |
EP1307197A2 (en) | 2003-05-07 |
ATE322266T1 (de) | 2006-04-15 |
US7435726B2 (en) | 2008-10-14 |
ES2258084T3 (es) | 2006-08-16 |
KR100790589B1 (ko) | 2008-01-02 |
WO2001087307A2 (en) | 2001-11-22 |
US20020035090A1 (en) | 2002-03-21 |
PT1307197E (pt) | 2006-08-31 |
CA2408707A1 (en) | 2001-11-22 |
HK1054502A1 (en) | 2003-12-05 |
KR20030025922A (ko) | 2003-03-29 |
WO2001087307A3 (en) | 2002-07-25 |
AU2001261474B2 (en) | 2006-03-09 |
US20050148524A1 (en) | 2005-07-07 |
JP5409981B2 (ja) | 2014-02-05 |
AU6147401A (en) | 2001-11-26 |
AR029084A1 (es) | 2003-06-04 |
TWI289449B (en) | 2007-11-11 |
JP2003533484A (ja) | 2003-11-11 |
ZA200209638B (en) | 2003-11-27 |
DK1307197T3 (da) | 2006-07-03 |
CA2408707C (en) | 2010-04-13 |
NZ522767A (en) | 2004-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA02011218A (es) | Composiciones y metodos para el tratamiento de cancer. | |
HK1053975A1 (en) | Compositions for the treatment of colorectal cancer comprising thalidomide and irinotecan | |
CR20220614A (es) | 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cáncer | |
WO2002043720A3 (en) | Compositions comprising temozolomide and thalidomide and methods for the treatment of cancer | |
WO2007062093A3 (en) | Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor | |
WO2005043971A3 (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain | |
HK1046093A1 (en) | Docetaxel in combination with rhumab her2 for the treatment of cancers. | |
MXPA05012155A (es) | Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades. | |
WO2005117954A3 (en) | Compositions and methods for treatment of neovascular diseases | |
MY142019A (en) | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | |
TW200626159A (en) | Therapeutic combinations comprising poly (ADP-ribose) polymerases inhibitor | |
TW200633700A (en) | Methods of using temozolomide formulation intrathecally in the treatment of cancers | |
TW200501945A (en) | Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases | |
WO2005046593A3 (en) | Methods and compositions using thalidomide for the treatment and management of cancers and other diseases. | |
WO2001068125A3 (en) | Methods and compositions for the treatment and prevention of erectile dysfunction | |
AP1780A (en) | Use of cox-2 inhibitors for preventing immunodeficiency. | |
WO2004037207A3 (en) | Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain | |
MX2022000430A (es) | Administracion de agonista de sting e inhibidores de puntos de control. | |
WO2005025501A3 (en) | Co-administration of polysaccharide with a chemotherapeutic agent for the treatment of cancer | |
EP1503748A4 (en) | DRUGS TO REDUCE TAXAN-INDUCED NEUROTOXICITY | |
WO2005009363A3 (en) | Treatment of pre-cancerous conditions and prevention of cancer using pcdgf-based therapies | |
TW200503683A (en) | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain | |
WO2004041190A3 (en) | Composition for the treatment of macular degenration | |
WO2002080895A3 (en) | Treatment of malaria with farsenyl protein transferase inhibitors | |
WO2004029025A3 (en) | Methods and compositions for the treatment of autoimmune disorders using clofarabine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |